At least 10 physicians received more than $20,000 in payments and other transfers of value from biotechnology giant Amgen in the first quarter of this year, according to newly public data published by the company.
As part of a corporate integrity agreement Amgen reached with the U.S. Justice Department in December over the marketing of its anemia drug Aranesp, the company is required to disclose payments and other transfers of value it makes to physicians. The Thousand Oaks, Calif.-based firm posted its first data set on Sunday, in a format that makes it difficult to transfer data into a spreadsheet format for analysis.
The 1,792-page (PDF) provides the name of the reportable party, the city he or she works in, the recipient, the nature of the payment and the payment amount. Amgen did not disclose total spending for the quarter.